Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Cystoscopy is the gold standard clinical diagnosis of human bladder cancer (BC). As cystoscopy is expensive and invasive, it compromises patients' compliance toward surveillance screening and challenges the detection of recurrent BC. Therefore, the development of a noninvasive method for the diagnosis and surveillance of BC and the elucidation of BC progression become pertinent. In this study, urine samples from 38 BC patients and 61 non-BC controls were subjected to urinary metabotyping using two-dimensional gas chromatography time-of-flight mass spectrometry (GC×GC-TOFMS). Subsequent to data preprocessing and chemometric analysis, the orthogonal partial least-squares discriminant analysis (OPLS-DA, R2X=0.278, R2Y=0.904 and Q2Y (cumulative)=0.398) model was validated using permutation tests and receiver operating characteristic (ROC) analysis. Marker metabolites were further screened from the OPLS-DA model using statistical tests. GC×GC-TOFMS urinary metabotyping demonstrated 100% specificity and 71% sensitivity in detecting BC, while 100% specificity and 46% sensitivity were observed via cytology. In addition, the model revealed 46 metabolites that characterize human BC. Among the perturbed metabolic pathways, our clinical finding on the alteration of the tryptophan-quinolinic metabolic axis in BC suggested the potential roles of kynurenine in the malignancy and therapy of BC. In conclusion, global urinary metabotyping holds potential for the noninvasive diagnosis and surveillance of BC in clinics. In addition, perturbed metabolic pathways gleaned from urinary metabotyping shed new and established insights on the biology of human BC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a study of urinary metabolites of bladder cancer cases compared with non-bladder cancer controls found significant perturbations of the kynurenine pathway, with tryptophan levels consistently lower in cases (Pasikanti et al., 2013).”
From Effects of exposure to water disinfection by-products in a swimming pool: A metabolome-wide association study (2018) · cites this paper as Pasikanti et al., 2013
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999) · Xenobiotica · doi:10.1080/004982599238047 · Cited by 3,895
Metabolomics—the link between genotypes and phenotypes
Fiehn, O. (2002) · Plant Molecular Biology · doi:10.1023/a:1013713905833 · Cited by 3,445
HMDB: the Human Metabolome Database
Wishart, D. S., Tzur, D., Knox, C., Eisner, R., Guo, A. C., Young, N., Cheng, D., Jewell, K., Arndt, D., Sawhney, S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl923 · Cited by 3,231
Metabolomics — the link between genotypes and phenotypes
Fiehn, O. (2002) · Functional Genomics · doi:10.1007/978-94-010-0448-0_11 · Cited by 3,167
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,234
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199812000-00001 · Cited by 1,578
GMD@CSB.DB: the Golm Metabolome Database
Kopka, J., Schauer, N., Krueger, S., Birkemeyer, C., Usadel, B., Bergmuller, E., Dormann, P., Weckwerth, W., Gibon, Y., Stitt, M., et al. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti236 · Cited by 1,382
Research works printed but not linked: 3
- Onuki T., 2007, Hinyokika Kiyo, 53, 449
- Panichi S., 1999, Ann. Ital. Chir., 70, 937
- Nyholm K. K., 1975, Biomedicine, 22, 509
Cited by
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Guide to Metabolomics Analysis: A Bioinformatics Workflow
Chen, Y., Li, E.-M., & Xu, L.-Y. (2022) · Metabolites · doi:10.3390/metabo12040357 · Cited by 351
Metabolic phenotype of bladder cancer
Massari, F., Ciccarese, C., Santoni, M., Iacovelli, R., Mazzucchelli, R., Piva, F., Scarpelli, M., Berardi, R., Tortora, G., Lopez-Beltran, A., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.005 · Cited by 334
“demonstrated by urinary metabotyping using two-dimensional gas chromatography time-of-flight mass spectrometry (GC GC–TOFMS) down-regulation of glycerol (end product of triglycerides hydrolysis) in bladder cancer compared with non-cancer patients [87].”
MethodEmerging field of metabolomics: Big promise for cancer biomarker identification and drug discovery
Patel, S., & Ahmed, S. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.12.020 · Cited by 173
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Dinges, S. S., Hohm, A., Vandergrift, L. A., Nowak, J., Habbel, P., Kaltashov, I. A., & Cheng, L. L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0185-3 · Cited by 161
Untargeted metabolomics analysis of esophageal squamous cell cancer progression
Yang, T., Hui, R., Nouws, J., Sauler, M., Zeng, T., & Wu, Q. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03311-z · Cited by 109
“To prevent overfitting, a permutation test (n = 200) in the SIMCA-P software package was applied to the OPLS-DA model [28, 29].”
MethodPeng, J., Chen, Y., Chen, C., & Li, L. (2014) · Analytical Chemistry · doi:10.1021/ac5011684 · Cited by 100
van Veldhoven, K., Keski-Rahkonen, P., Barupal, D. K., Villanueva, C. M., Font-Ribera, L., Scalbert, A., Bodinier, B., Grimalt, J. O., Zwiener, C., Vlaanderen, J., et al. (2018) · Environment International · doi:10.1016/j.envint.2017.11.017 · Cited by 94
“Moreover, a study of urinary metabolites of bladder cancer cases compared with non-bladder cancer controls found significant perturbations of the kynurenine pathway, with tryptophan levels consistently lower in cases (Pasikanti et al., 2013).”
BackgroundA review of validated biomarkers obtained through metabolomics
López-López, Á., López‐Gonzálvez, Á., Barker‐Tejeda, T. C., & Barbas, C. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1481391 · Cited by 107
Applications of Metabolomics in Cancer Studies
Armitage, E. G., & Ciborowski, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-47656-8_9 · Cited by 97
Artificially Intelligent Olfaction for Fast and Noninvasive Diagnosis of Bladder Cancer from Urine
Jian, Y., Zhang, N., Liu, T., Zhu, Y., Wang, D., Dong, H., Guo, L., Qu, D., Jiang, X., Du, T., et al. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00467 · Cited by 82
Comprehensive Targeted Metabolomic Assay for Urine Analysis
Zheng, J., Zhang, L., Johnson, M., Mandal, R., & Wishart, D. S. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01682 · Cited by 75
Bladder cancer recurrence surveillance by urine metabolomics analysis
Loras, A., Trassierra, M., Sanjuan-Herráez, J. D., Martínez‐Bisbal, M. C., Castell, J. V., Quintás‐Cardama, A., & Ruiz-Cerdá, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-27538-3 · Cited by 80
Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems
Rodrigues, D., Jerónimo, C., Henrique, R., Belo, L., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2016) · International Journal of Cancer · doi:10.1002/ijc.30016 · Cited by 74
Zhou, Y., Song, R., Ma, C., Zhou, L., Liu, X., Yin, P., Zhang, Z., Ying-hao, S. U. N., Xu, C., Lu, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14988 · Cited by 60
Metabolomics in bladder cancer: a systematic review.
Cheng, Y., Yang, X. F., Deng, X., Zhang, X., Li, P., Tao, J., Qin, C., Wei, J., & Lü, Q. (2015) · PubMed · Cited by 68
Burton, C., & Ma, Y. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170914102236 · Cited by 61
Recognition of early and late stages of bladder cancer using metabolites and machine learning
Kouznetsova, V. L., Kim, E., Romm, E. L., Zhu, A., & Tsigelny, I. F. (2019) · Metabolomics · doi:10.1007/s11306-019-1555-9 · Cited by 62
“Metabolites described by Pasikanti et al. (2013) were interpreted to be those of early stage because all patients had either Ta or T1 stage cancer.”
BackgroundAn, R., Yu, H., Wang, Y., Lü, J., Gao, Y., Xie, X., & Zhang, J. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00289-6 · Cited by 71
“At present, metabolomics technology has successfully been used to identify biomarkers in various tumors, such as lung cancer [14], pancreatic ductal adenocarcinoma [15], prostate cancer [16], bladder cancer [17], and breast cancer [18].”
Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer
Tan, G., Wang, H., Yuan, J., Qin, W., Dong, X. W., Wu, H., & Meng, P. (2017) · Scientific Reports · doi:10.1038/srep46176 · Cited by 64
Kim, W. T., Yun, S. J., Yan, C., Jeong, P., Kim, Y. H., Lee, I.-S., Kang, H.-W., Park, S., Moon, S., Choi, Y. H., et al. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.4.865 · Cited by 53
“Our previous study identified twelve urinary metabolites, including carnitine, and their derivatives and melatonin, as potential diagnostic biomarkers for BCA.13 The following bioinformatics analysis showed that these metabolites were enriched in the carnitine-acylcarnitine or tryptophan metabolic pathways.”
BackgroundInfluentialRecent advances in the metabolomic study of bladder cancer
Amara, C. S., Vantaku, V., Lotan, Y., & Putluri, N. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1583105 · Cited by 53
“Metabolites involved in tryptophan metabolism pathway such as kynurenine and tryptophan have been proposed as potential urinary candidate biomarkers and also serve as therapeutic targets for BLCA treatment [17,60].”
BackgroundRodrigues, D., Pinto, J., Araújo, A. M., Monteiro‐Reis, S., Jerónimo, C., Henrique, R., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2018) · Metabolomics · doi:10.1007/s11306-018-1361-9 · Cited by 47
Metabonomic Profiling of Bladder Cancer
Chan, E. C. Y., Pasikanti, K. K., Hong, Y., Ho, P. C., Mahendran, R., Mani, L. R. N., Chiong, E., & Esuvaranathan, K. (2014) · Journal of Proteome Research · doi:10.1021/pr500966h · Cited by 49
Self-citationCurrent state of bioanalytical chromatography in clinical analysis
Vlčková, H., Pilařová, V., Svobodová, P., Plíšek, J., Švec, F., & Nováková, L. (2018) · The Analyst · doi:10.1039/c7an01807j · Cited by 49
Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum
Penney, K. L., Tyekucheva, S., Rosenthal, J., Elfandy, H., Carelli, R., Borgstein, S., Zadra, G., Fanelli, G. N., Stefanizzi, L., Giunchi, F., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0548 · Cited by 50
Pinto, J., Amaro, F., Lima, A. R., Carvalho‐Maia, C., Jerónimo, C., Henrique, R., Bastos, M. D. L., Carvalho, M. C., & de Pinho, P. G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00936 · Cited by 43
Metabolic Perturbation and Potential Markers in Patients with Esophageal Cancer
Zhu, X., Wang, K., Liu, G., Wang, Y., Xu, J., Liu, L., Li, M., Shi, J., Aa, J., & Lianzhen, Y. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/5469597 · Cited by 41
Rodrigues, D., Monteiro, M. S., Jerónimo, C., Henrique, R., Belo, L., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.018 · Cited by 40
Łuczykowski, K., Warmuzińska, N., Operacz, S., Stryjak, I., Bogusiewicz, J., Jacyna, J., Wawrzyniak, R., Struck‐Lewicka, W., Markuszewski, M. J., & Bojko, B. (2021) · Molecules · doi:10.3390/molecules26082194 · Cited by 38
“Decreased concentration of gluconic acid in the urine of the bladder cancer patients has been reported previously [16,17].”
Yan, Z., & Yan, R. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.08.056 · Cited by 37
Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study
Oto, J., Fernández‐Pardo, Á., Roca, M., Plana, E., Solmoirago, M. J., Sánchez-González, J. V., Vera-Donoso, C. D., Martínez-Sarmiento, M., España, F., Navarro, S., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103723 · Cited by 37
Advances in urinary biomarker discovery in urological research
Kim, J., Kim, W. T., & Kim, W. (2020) · Korean journal of urology · doi:10.4111/icu.2020.61.s1.s8 · Cited by 36
“On the study of glycolysis-related metabolites, decreased fructose levels and increased lactate levels were showed in BC patients [73,75].”
BackgroundInfluentialYumba-Mpanga, A., Siluk, D., Jacyna, J., Szerkus, O., Wawrzyniak, R., Markuszewski, M., Matuszewski, M., Kaliszan, R., & Markuszewski, M. J. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.01.055 · Cited by 33
Analysis of VOCs in Urine Samples Directed towards of Bladder Cancer Detection
Ligor, T., Adamczyk, P., Kowalkowski, T., Ratiu, I., Wenda-Piesik, A., & Buszewski, B. (2022) · Molecules · doi:10.3390/molecules27155023 · Cited by 35
“The method demonstrates 71% sensitivity and 100% specificity in the detection of BC [24].”
MethodPutative markers for the detection of early-stage bladder cancer selected by urine metabolomics
Lin, J., Juo, B.-R., Yeh, Y.-H., Fu, S.-H., Chen, Y., Chen, C., & Wu, K. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04235-z · Cited by 30
Discovering Biomarkers in Bladder Cancer by Metabolomics
Zhang, W., Zhang, Z.-W., Guo, Y., Wang, L., Mao, S., Zhang, J., Liu, M., & Yao, X. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0229 · Cited by 29
Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications
Wu, S., Li, R., Jiang, Y., Yu, J., Zheng, J., Li, Z., Li, M., Xin, K., Wang, Y., Xu, Z., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115027 · Cited by 33
Kok, M. G. M., Somsen, G. W., & de Jong, G. J. (2014) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2014.06.004 · Cited by 30
Oto, J., Fernández‐Pardo, Á., Roca, M., Plana, E., Cana, F., Herranz, R., Pérez‐Ardavín, J., Vera-Donoso, C. D., Martínez-Sarmiento, M., & Medina, P. (2022) · World Journal of Urology · doi:10.1007/s00345-022-04136-7 · Cited by 26
“[28] observed an increase of p-cresol glucuronide in urine of BC patients compared to non-bladder cancer controls, but no additional studies have identified this metabolite in urine of BC patients.”
GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells
Rodrigues, D., Pinto, J., Araújo, A. M., Jerónimo, C., Henrique, R., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2019) · Metabolites · doi:10.3390/metabo9010018 · Cited by 24
Morad, H. M., Abou‐Elzahab, M. M., Aref, S., & El-Sokkary, A. M. A. (2022) · ACS Omega · doi:10.1021/acsomega.2c00083 · Cited by 26
Belugina, R., Karpushchenko, E., Sleptsov, A., Протощак, В. В., Legin, A. V., & Kirsanov, D. O. (2021) · Talanta · doi:10.1016/j.talanta.2021.122696 · Cited by 24
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer
Loras, A., Segovia, C., & Ruiz-Cerdá, J. L. (2021) · Cancers · doi:10.3390/cancers13112719 · Cited by 23
Yumba-Mpanga, A., Struck‐Lewicka, W., Wawrzyniak, R., Markuszewski, M., Roslan, M., Kaliszan, R., & Markuszewski, M. J. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006150326 · Cited by 23
Multidimensional Gas Chromatography Methods for Bioanalytical Research
Wong, Y. F., Hartmann, C., & Marriott, P. J. (2014) · Bioanalysis · doi:10.4155/bio.14.186 · Cited by 21
Gondal, M. N., & Chaudhary, S. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712505 · Cited by 34
States of quinolinic acid excess in urine: A systematic review of human studies
Saadé, M. C., Clark, A. J., & Parikh, S. M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1070435 · Cited by 23
“(34) Bladder cancer 99 Two-dimensional gas chromatography time-of-flight mass spectrometry Develop a non-invasive method to diagnose and follow-up bladder cancer.”
BackgroundMethodWhat clinical metabolomics will bring to the medicine of tomorrow
Gouëllec, A. L., Plazy, C., & Toussaint, B. (2023) · Frontiers in Analytical Science · doi:10.3389/frans.2023.1142606 · Cited by 24
“In four studies using MS, comparing the metabolic profiles of urine from bladder cancer patients and healthy subjects, OPLS- DA and PLS-DA models with crossvalidation (Pasikanti et al., 2010; Huang et al., 2011; Pasikanti et al., 2013) or a preliminary test cohort (Issaq et al.”
MethodYang, E., Jing, S., Wang, F., Wang, H., Fu, S., Yang, L., Tian, J., Golijanin, D. J., El‐Deiry, W. S., Cheng, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07068-9 · Cited by 21
Kim, S., Yin, X., Prodhan, M. A. I., Zhang, X., Zhong, Z., & Kato, I. (2019) · Journal of Chromatographic Science · doi:10.1093/chromsci/bmz011 · Cited by 19
“Whereas applications of GC × GC–MS have been rather limited in studies of cancer biomarkers with a few publications on nongastrointestinal cancers (30, 31), wealth of GC × GC–MS data have been published in various types of metabolomic studies in humans.”
BackgroundUrinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?
Petrella, G., Ciufolini, G., Vago, R., & Cicero, D. O. (2021) · Metabolites · doi:10.3390/metabo11110756 · Cited by 22
“, 2013 [50] GC-TOF non-BC (61) 59 60 ± 13 NMIBC (38) 84 68 ± 11”
Li, Y., Jiang, L., Wang, Z., Wang, Y., Cao, X., Meng, L., Fan, J., Xiong, C., & Nie, Z. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01890 · Cited by 21
Su, X., Dong, C., Liao, W., & Liu, W. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03161-z · Cited by 18
“Some proteins in urine such as NMP22, Complement factor H-related protein, BLCA-4, and apolipoproteins [26] as well as various metabolites such as taurine, citrate, succinate [27, 28], desaminotyrosine, erythritol, d-ribose, ribitol, d-fructose, d-mannose, and d-galactose [29] have been found to be biomarkers for the…”
BackgroundMetabolomics for the diagnosis of bladder cancer: A systematic review
García‐Perdomo, H. A., Dávila‐Raigoza, A. M., & Korkes, F. (2023) · Asian journal of urology · doi:10.1016/j.ajur.2022.11.005 · Cited by 19
Discovery of urine biomarkers for bladder cancer via global metabolomics
Shi, H., Li, X., Zhang, Q., Yang, H., & Zhang, X. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1171903 · Cited by 20
“…from building an entirely comprehensive metabolic network from the recent limited findings, several recommended pathways, such as the kynurenine pathway of tryptophan metabolism (Pasikanti et al., 2013) and the ketone synthesis and degradation pathway (Zhang et al., 2012b), have been identified.”
BackgroundMethodInfluentialUterine Metabolomics Reveals Protection of Taohong Siwu Decoction Against Abnormal Uterine Bleeding
Zhang, Y., Zuo, C., Han, L., Liu, X., Chen, W., Wang, J., Gui, S., Peng, C., & Peng, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.507113 · Cited by 20
“The statistical model is generally considered effective and no overfitting when the Q2intercept value is negative and the R2-value is lower than the original R2-value (Pasikanti et al., 2013; Triba et al., 2015; Zhang et al., 2017).”
BackgroundShahid, M., Yeon, A., & Kim, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11627 · Cited by 17
Yang, B., Liao, G., Wen, X., Chen, W., Cheng, S., Stolzenburg, J., Ganzer, R., & Neuhaus, J. (2017) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1600441 · Cited by 17
“In conclusion, MS-based metabolomics can improve BCa detection and risk stratification but the financial burden may hinder comprehensive routine implementation.”
BackgroundResultInfluentialLee, S.-J., Ku, J. Y., Kang, B. J., Kim, K. H., Ha, H. K., & Kim, S. (2021) · Metabolites · doi:10.3390/metabo11090591 · Cited by 20
Bhattacharyya, N. K., Mukherjee, D., Singh, S., Ghosh, R., Karmakar, S., Mallick, A., Chattopadhyay, A., Mondal, P., Mondal, T. K., Bhattacharyya, D., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114764 · Cited by 17
Doménech‐Carbó, A., Pontones, J. L., Doménech-Casasús, C., Artés, J., Villaroya, S., & Ramos, D. (2018) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2018.03.048 · Cited by 16
Not Only Immune Escape—The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis
Kwiatkowska, I., Hermanowicz, J. M., Przybyszewska-Podstawka, A., & Pawlak, D. (2021) · Cancers · doi:10.3390/cancers13112667 · Cited by 20
Cross-Classification of Human Urinary Lipidome by Sex, Age, and Body Mass Index
Okemoto, K., Maekawa, K., Tajima, Y., Tohkin, M., & Saito, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168188 · Cited by 15
Zhou, X., Zheng, M., Wang, Q.-E., Aa, J., Cao, B., & Li, J. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02836-7 · Cited by 19
Urinary Metabolic Biomarkers in Cancer Patients: An Overview
Matteis, S. D., Bonafè, M., & Giudetti, A. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1354-2_18 · Cited by 14
Jian, Y., Zhang, N., Bi, Y., Liu, X., Fan, J., Wu, W., & Liu, T. (2024) · ACS Sensors · doi:10.1021/acssensors.4c02073 · Cited by 14
Manzi, M., Riquelme, G., Zabalegui, N., & Monge, M. E. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.112905 · Cited by 18
Zhu, S., Huang, Z., & Nabi, G. (2019) · Biomedical Optics Express · doi:10.1364/boe.380629 · Cited by 15
Hudolin, T., Mengus, C., Coulot, J., Kaštelan, Ž., El‐Saleh, A., & Spagnoli, G. C. (2017) · Anticancer Research · doi:10.21873/anticanres.11458 · Cited by 13
Jiang, X., Gao, F., Chen, X., Yu, Y., Ding, G., & Wu, J. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00340 · Cited by 12
Edwards, M., & Górecki, T. (2015) · Journal of Chromatography A · doi:10.1016/j.chroma.2015.05.014 · Cited by 12
Effects of Bailing capsule on diabetic nephropathy based on UPLC-MS urine metabolomics
Xu, J., Yuan, Q., Wu, K., Li, X., Zhao, Y., & Li, X. (2019) · RSC Advances · doi:10.1039/c9ra05046a · Cited by 11
Kim, J., Ahn, J. K., Cheong, Y. E., Lee, S., Cha, H., & Kim, K. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230072 · Cited by 18
UPLC-Q-TOF/MS-based urine metabolomics for the diagnosis and staging of bladder cancer
Shi, X., Zheng, W., He, B., Huang, L., Zhong, Q., Yang, Y., Zhou, T., & Huang, Y. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.120022 · Cited by 12
Yang, C., Sun, X. L., Wang, H., Lu, T., Wu, K., Guan, Y., Tang, J., Liang, J., Sun, R., Guo, Z., et al. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4347 · Cited by 12
Nizioł, J., Ossoliński, K., Płaza‐Altamer, A., Kołodziej, A., Ossolińska, A., Ossoliński, T., Krupa, Z., & Ruman, T. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.115966 · Cited by 9
Zaid, A., Khan, M. S., Yan, D., Marriott, P. J., & Wong, Y. F. (2022) · The Analyst · doi:10.1039/d2an00584k · Cited by 11
Pan, W., Xing, J., Chen, X., Xue, R., Xu, G., Li, S., Yi, H., Jin, B., Wan, X., Sang, X., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003919 · Cited by 12
Rapid screening for genitourinary cancers: mass spectrometry-based metabolic fingerprinting of urine
Wang, X. D., Li, Y., Fan, J., He, L., Chen, J., Liu, H., & Nie, Z. (2022) · Chemical Communications · doi:10.1039/d2cc02329f · Cited by 7
Lipid Metabolism Profiling and Bladder Cancer
Beşiroğlu, H. (2015) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000154 · Cited by 9
Zhong, Q., Shao, L., Yao, Y., Chen, S., Lv, X., Liu, Z., Zhu, S., & Yan, Z. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05595-0 · Cited by 5
“Furthermore, previous study has shown significant differences in the urinary metabolomic profiles between healthy individuals and BC patients through gas chromatography-mass spectrometry (GC–MS) [25], so urine may be the most ideal sample for BC diagnosis and monitoring.”
Metabolomics for searching validated biomarkers in cancer studies: a decade in review
López-López, Á., López‐Gonzálvez, Á., & Barbas, C. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2368603 · Cited by 9
“Out of the twelve BC studies selected, urine was employed by nine [8–16], which seems to be the ideal sample type because of the direct contact with the tumor and minimally invasive nature, although subject to high variability.”
Adutwum, L. A., Kwao, J. K., & Harynuk, J. J. (2021) · Journal of Separation Science · doi:10.1002/jssc.202001127 · Cited by 5
Li, L., Wen, X., Li, X., Yan, Y., Wang, J., Zhao, X., Tian, Y., Ling, R., & Duan, Y. (2024) · Metabolomics · doi:10.1007/s11306-024-02119-w · Cited by 4
“…profiles in biological systems (i.e. cells, tissues, organs, biological fluids, or organisms) (Brown et al., 2005), in particular for cancer studies (Bouza et al., 2017; Huang et al., 2013; Lima et al., 2019; Nokhoijav et al., 2022; Pasikanti et al., 2013; Tsou et al., 2021; Zhong et al., 2016).”
Metabonomic Diagnosis of Bladder Cancer: What are The Advantages and Considerations?
Hong, Y., Esuvaranathan, K., Pasikanti, K. K., & Chan, E. C. Y. (2015) · Bioanalysis · doi:10.4155/bio.15.192 · Cited by 4
Self-citationFang, M., Liu, F., Huang, L., Wu, L., Guo, L., & Wan, Y. (2020) · International Journal of Analytical Chemistry · doi:10.1155/2020/8839215 · Cited by 4
“[37] have developed a noninvasive method for the diagnosis and surveillance of BC progression by using the GC×GC-MS method.”
MethodLiang, W., Vasini, B., Clayton, J., Ma, J.-X., & Karamichos, D. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110507 · Cited by 4
Insight into Fructose-to-Sucrose Ratio as the Potential Target of Urinalysis in Bladder Cancer
Zhou, D., Huang, J., Zheng, H., Liu, Y., Zhu, S., & Du, Y. (2024) · Metabolites · doi:10.3390/metabo14060345 · Cited by 2
Integrated technologies in the post-genomic era for discovery of bladder cancer urinary markers
Eissa, S., & Matboli, M. (2013) · World Journal of Clinical Urology · doi:10.5410/wjcu.v2.i3.20 · Cited by 2
Metabolomics and Bladder Cancer: Current State and Future Perspectives
Antunes, H. P., Tavares-da-Silva, E., Marques, I. A., Carvalho, J., Abrantes, A. M., Alves, M. G., Botelho, M. F., & Figueiredo, A. (2018) · Acta Urológica Portuguesa · doi:10.24915/aup.35.1-2.64 · Cited by 3
Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer
Jin, F., Shahid, M., & Kim, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63908-2_5 · Cited by 2
Vishwanath, V., Mayer, D., Fu, D., Wnorowski, A. M., & Siddiqui, M. M. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.08.27 · Cited by 2
“This evidence is consistent with our discussion above detailing bladder cancer’s increased use of glycolysis and impairment of the TCA cycle, which would also contribute to increased levels of Acetyl CoA in the mitochondria.”
BackgroundInfluentialNMR-Based Metabolic Profiling: Methods and Application in Cancer Biomarker Discovery.
Ge, W. (2014) · Deep Blue (University of Michigan) · Cited by 2
Role of Kynurenine Pathway in Cancer Biology
Mowat, C. G. (2015) · Springer eBooks · doi:10.1007/978-3-319-11870-3_21 · Cited by 1
de Pinho, P. G., Carvalho, M. C., & Pinto, J. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-346-7 · Cited by 1
Chemometrics-aided Metabolic Fingerprint Method Applied in Bladder Cancer Stages Differentiating
Qin, Y., Chen, L., Huang, J., ZHANG, S.-H., & Xiao, Z. (2018) · Digital Chinese Medicine · doi:10.1016/s2589-3777(19)30028-x
Huang, P., Huang, X., Sun, A., Guo, J., Gong, H., Li, S., & Lü, X. (2020) · Medical Research Archives · doi:10.18103/mra.v8i11.2239
Tryptophan Metabolism and IDO/TDO Expression in Bladder Cancer: A Case‐control Study in Singapore
Lee, S. H., Esuvaranathan, K., Chiong, E., Thamboo, T. P., Choo, S. N., Raman, L. N. M., Mahendran, R., & Chan, E. C. Y. (2018) · The FASEB Journal · doi:10.1096/fasebj.2018.32.1_supplement.566.13
Self-citationWhither Gas Chromatography? New Tools ~ New Solutions
Marriott, P. J., Wong, Y. F., & Hill, J. E. (2022) · LCGC North America · doi:10.56530/lcgc.na.sb8579x8
Metadata
- Authors
- Pasikanti, K. K., Esuvaranathan, K., Hong, Y., Ho, P. C., Mahendran, R., Raman Nee Mani, L., Chiong, E., & Chan, E. C. Y.
- Affiliations
- National University of Singapore (SG)
- National University Health System (SG)
- Department of Surgery, National University Health System, 5 Lower Kent Ridge Road, Singapore 119074
- Corresponding author
- Esuvaranathan, Kesavan
- Chan, Eric Chun Yong
- ORCID
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-08-07
- Volume
- 12
- Issue
- 9
- Pages
- 3865-3873
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- OpenAlex
- W2327028950
- Cited by
- 113
- References
- 49
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 14 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 8 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 1
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Proteome Research (publishedVersion)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Physical Sciences › Engineering › Biomedical Engineering › Advanced Chemical Sensor Technologies
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- bladder cancer, non-invasive diagnosis, cancer surveillance, tryptophan metabolism, kynurenine, quinolinic acid, biomarkers, cystoscopy alternative
- MeSH terms
- Aged, Urinary Bladder Neoplasms, Creatinine, Female, Humans, Male, Gas Chromatography-Mass Spectrometry, Middle Aged, Tryptophan, Biomarkers, Tumor, Case-Control Studies, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.